ATLL
MCID: ADL104
MIFTS: 52

Adult T-Cell Leukemia/lymphoma (ATLL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Adult T-Cell Leukemia/lymphoma

MalaCards integrated aliases for Adult T-Cell Leukemia/lymphoma:

Name: Adult T-Cell Leukemia/lymphoma 11 19 58 36 75
Adult T-Cell Leukemia 11 14
Atll 19 58
Adult T-Cell Leukaemia/lymphoma 19
Leukemia-Lymphoma, Adult T-Cell 43
T Cell Leukemia Lymphoma Adult 53
Adult T-Cell Lymphoma/leukemia 71
Adult T-Cell Leukaemia 19
Adult T-Cell Lymphoma 19
Leukemia, T-Cell 71

Characteristics:


Inheritance:

Multigenic/multifactorial 58

Prevelance:

1-9/100000 (Europe) 58

Age Of Onset:

Adult 58

Classifications:

Orphanet: 58  
Rare skin diseases
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:0050523
MeSH 43 D015459
NCIt 49 C3184
SNOMED-CT 68 77430005
ICD10 31 C91.5
MESH via Orphanet 44 D015459
ICD10 via Orphanet 32 C91.5
UMLS via Orphanet 72 C0023493
Orphanet 58 ORPHA86875
UMLS 71 C0023492 C0023493

Summaries for Adult T-Cell Leukemia/lymphoma

GARD: 19 Adult T-cell leukemia/lymphoma (ATL) is is a rare and aggressive T-cell lymphoma that is linked to infection by the human T-cell lymphotropic virus 1 (HTLV-1). The exact mechanism by which HTLV-I infection causes the ATL is unknown. The clinical features of ATL include generalized swelling of the lymph nodes (lymphadenopathy), increased liver and spleen size (hepatosplenomegaly), immunosuppression, high levels of calcium in the blood, lytic bone lesions (spots that appear as 'holes' on a standard bone x-ray), and skin lesions. There are four basic clinical variants of ATL: acute (60% of cases), lymphomatous (20 % of cases), chronic (10% of cases) and smoldering (10% of cases).

MalaCards based summary: Adult T-Cell Leukemia/lymphoma, also known as adult t-cell leukemia, is related to t-cell adult acute lymphocytic leukemia and t-cell acute lymphoblastic leukemia. An important gene associated with Adult T-Cell Leukemia/lymphoma is BCL11B (BCL11 Transcription Factor B), and among its related pathways/superpathways are NF-kappaB Signaling and CD28 Signaling in T-Helper Cell. The drugs Zidovudine and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone, and related phenotypes are immune system and hematopoietic system

Orphanet: 58 A rare, virus associated tumor due to human T-cell leukemia virus type 1 or human T-cell lymphotropic virus type 1 (HTLV-1) and is characterized by the presence of anti-HTLV-1 antibodies, and malignant, mature, medium-sized T cells with condensed chromatin and polylobated nuclei. The malignant cells exhibit a mature CD4+ T cells phenotype and express CD2, CD5, CD25, CD45RO, HLA-DR, and T-cell receptor αβ. Presentation is heterogeneous and is typically of aggressive leukemia or lymphoma, variable skin eruptions, and visceral organ involvement.

Disease Ontology: 11 A T-cell acute leukemia that results in abnormal increase of lymphocytes, derives from T-cells, has material basis in Human T-lymphotropic virus 1 (HTLV-1), which is transmitted by sexual contact, transmitted by contaminated needles used by intravenous-drug users, and transmitted by breast feeding. The infection results in formation of skin lesions.

Wikipedia: 75 Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood... more...

Related Diseases for Adult T-Cell Leukemia/lymphoma

Diseases related to Adult T-Cell Leukemia/lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 930)
# Related Disease Score Top Affiliating Genes
1 t-cell adult acute lymphocytic leukemia 32.3 TNFRSF8 MIR28 IL2 HBZ CNTN2 CENPV
2 t-cell acute lymphoblastic leukemia 31.8 TNFRSF8 PTHLH MIR155 KDM4C IL2RA IL2
3 mycosis fungoides 31.6 TNFRSF8 MIR155 IL2RA IL2 CD7 CCR6
4 fungal infectious disease 31.6 IL2 ICOSLG H2AC18 CD8A CD4 CCR6
5 tropical spastic paraparesis 31.6 IL2RA IL2 HBZ CNTN2 CENPV CD8A
6 acute graft versus host disease 31.5 IL2RA IL2
7 spinal cord disease 31.4 MIR155 KDM4C ICOSLG HBZ H2AC18 CD8A
8 strongyloidiasis 31.4 HBZ CD7 CD4
9 lymphoma, hodgkin, classic 31.4 TNFRSF8 MIR155 KDM4C IL2RA IL2 ICOSLG
10 exanthem 31.3 IL2 ICOSLG H2AC18 CD8A CD4 CCR6
11 scabies 31.2 TNFRSF8 CD8A CD4 CCR6
12 human cytomegalovirus infection 31.1 CD8A CD4 CCR6
13 lymphadenitis 31.1 IL2RA ICOSLG CCR6
14 primary cutaneous t-cell non-hodgkin lymphoma 31.1 TNFRSF8 MIR155 KDM4C IL2RA IL2 H2AC18
15 norwegian scabies 31.1 CD8A CD4
16 severe cutaneous adverse reaction 31.1 CD8A CD4 CCR6
17 pneumocystosis 31.1 IL2 CD8A CD4 CCR6
18 peripheral t-cell lymphoma 31.0 TNFRSF8 MIR155 KDM4C IL2RA ICOSLG H2AC18
19 respiratory failure 31.0 MIR155 IL2 H2AC18 CD8A CD4 CCR6
20 sezary's disease 31.0 TNFRSF8 MIR155 IL2RA IL2 CD8A CD7
21 herpes zoster 31.0 IL2 CD8A CD4 CCR6
22 severe combined immunodeficiency 30.9 TNFRSF8 IL2RA IL2 ICOSLG H2AC18 CD8A
23 hematologic cancer 30.9 TNFRSF8 PTHLH MIR28 MIR155 KDM4C IL2RA
24 lymphoblastic lymphoma 30.9 TNFRSF8 CD8A CD7
25 follicular mucinosis 30.9 TNFRSF8 CD8A CD7 CD4 CD2
26 pancytopenia 30.9 IL2RA H2AC18 CD8A CD7 CD4 CD2
27 cryptococcosis 30.9 CD8A CD4 CCR6
28 t-cell prolymphocytic leukemia 30.9 TNFRSF8 H2AC18 CD8A CD7 CD4 CD2
29 henoch-schoenlein purpura 30.9 ICOSLG CD4 CCR6
30 pfeiffer syndrome 30.8 TNFRSF8 IL2 H2AC18 CD8A CD4 CCR6
31 bacterial sepsis 30.8 ICOSLG CD8A CD4 CCR6
32 cryptococcal meningitis 30.8 IL2 CD8A CD4 CCR6
33 diffuse large b-cell lymphoma 30.8 TNFRSF8 MIR28 MIR155 KDM4C ICOSLG H2AC18
34 viral infectious disease 30.8 MIR155 IL2RA IL2 ICOSLG H2AC18 CD4
35 intestinal perforation 30.7 CD8A CD4 CCR6
36 alopecia areata 30.7 IL2RA IL2 ICOSLG
37 miliary tuberculosis 30.7 IL2 CD8A CD4
38 hemorrhagic cystitis 30.7 IL2 CD8A CD4
39 filarial elephantiasis 30.7 IL2 CD8A CD4
40 demyelinating polyneuropathy 30.7 CNTN2 CD8A CD4
41 oral candidiasis 30.7 CD8A CD4 CCR6
42 intermediate uveitis 30.7 IL2RA IL2 CD4 CCR6
43 acute retinal necrosis syndrome 30.7 CD8A CD4
44 nasal type extranodal nk/t-cell lymphoma 30.7 TNFRSF8 KDM4C CD2
45 keratoconjunctivitis sicca 30.7 ICOSLG CD4 CCR6
46 central nervous system lymphoma 30.6 TNFRSF8 KDM4C CD4
47 lymphoma, non-hodgkin, familial 30.6 TNFRSF8 MIR28 MIR155 KDM4C IL2RA IL2
48 viral pneumonia 30.6 IL2 CD8A CD4 CCR6
49 chickenpox 30.6 IL2 CD8A CD4 CCR6
50 severe covid-19 30.6 IL2 CD8A CD4 CCR6

Graphical network of the top 20 diseases related to Adult T-Cell Leukemia/lymphoma:



Diseases related to Adult T-Cell Leukemia/lymphoma

Symptoms & Phenotypes for Adult T-Cell Leukemia/lymphoma

MGI Mouse Phenotypes related to Adult T-Cell Leukemia/lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.8 ATL2 BCL11B CCR6 CD4 CD7 CD8A
2 hematopoietic system MP:0005397 9.5 ATL2 BCL11B CCR6 CD4 CD7 CD8A

Drugs & Therapeutics for Adult T-Cell Leukemia/lymphoma

Drugs for Adult T-Cell Leukemia/lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zidovudine Approved Phase 4 30516-87-1 35370
2
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
3
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
4
Daclizumab Investigational, Withdrawn Phase 4 152923-56-3
5 Antimetabolites Phase 4
6 Immunologic Factors Phase 4
7 Reverse Transcriptase Inhibitors Phase 4
8 Interferon alpha-2 Phase 4
9 interferons Phase 4
10 Interferon-alpha Phase 4
11 Neurotransmitter Agents Phase 4
12 Psychotropic Drugs Phase 4
13 Anticonvulsants Phase 4
14
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
15
Lenograstim Approved, Investigational Phase 3 135968-09-1
16
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
17
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
18
Aclarubicin Investigational Phase 3 57576-44-0
19 Adjuvants, Immunologic Phase 3
20
homoharringtonine Phase 3 3628
21
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
22
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
23
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
24
Iron Approved Phase 2 7439-89-6 29936
25
Deferasirox Approved, Investigational Phase 2 201530-41-8 214348 5493381
26
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
27
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
28
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
29
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
30
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
31
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
32
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
33
Vindesine Approved, Investigational Phase 2 59917-39-4, 53643-48-4 40839
34
Triamcinolone Approved, Vet_approved Phase 1, Phase 2 124-94-7 31307
35
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 1, Phase 2 62-33-9, 60-00-4 6049
36
Pentetic acid Approved Phase 1, Phase 2 67-43-6
37
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
38
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
39
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
40
Belinostat Approved, Investigational Phase 2 414864-00-9, 866323-14-0 53437714 6918638
41
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
42
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
43
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
44
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
45
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
46
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
47
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
48
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
49
Daunorubicin Approved Phase 2 20830-81-3 30323
50
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006

Interventional clinical trials:

(show top 50) (show all 155)
# Name Status NCT ID Phase Drugs
1 HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
2 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
3 Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b Terminated NCT00854581 Phase 4 Valproic Acid;Zidovudine
4 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Unknown status NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
5 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Unknown status NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
6 Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801. Completed NCT00145002 Phase 3 VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
7 A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients Recruiting NCT04446130 Phase 3 Decitabine combined with HAAG Regimen
8 Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia Unknown status NCT03613428 Phase 1, Phase 2 Ruxolitinib;Vincristine;Prednisone
9 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
10 Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma Completed NCT02631746 Phase 2
11 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
12 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
13 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
14 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
15 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
16 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
17 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
18 Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Completed NCT01626664 Phase 2 Pralatrexate;gemcitabine plus oxaliplatin;DHAP
19 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
20 A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
21 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
22 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
23 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
24 Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma Completed NCT00920790 Phase 2
25 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
26 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
27 Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma Completed NCT00082888 Phase 2 Tipifarnib
28 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
29 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
30 A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed NCT01261247 Phase 2 panobinostat
31 A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma Completed NCT01274533 Phase 2 Lenalidomide
32 Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma (Untreated Primary Disease) Completed NCT01173887 Phase 2 VCAP/AMP/VECP(mLSG15)
33 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
34 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
35 Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
36 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
37 A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma Completed NCT01724177 Phase 2 Lenalidomide
38 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
39 Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Completed NCT01378871 Phase 2 IMTOX-25
40 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
41 A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia Completed NCT00001941 Phase 1, Phase 2
42 PHASE I/II STUDY OF TAC-EXPRESSING ADULT T-CELL LEUKEMIA (ATL) WITH YTTRIUM-90 (90Y)-RADIOLABELED HUMANIZED ANTI-TAC AND CALCIUM-DTPA Completed NCT00019227 Phase 1, Phase 2 pentetic acid calcium
43 Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL) Completed NCT01712659 Phase 1, Phase 2 Ruxolitinib;ruxolitinib
44 A Phase 2b Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) Completed NCT02955589 Phase 2 HBI-8000
45 Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma Completed NCT00041327 Phase 2 Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
46 Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2 Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
47 A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use Completed NCT00095381 Phase 2 forodesine hydrochloride (BCX-1777)
48 German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
49 Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma Completed NCT00081874 Phase 1, Phase 2 RAD001
50 A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma Completed NCT00611208 Phase 2

Search NIH Clinical Center for Adult T-Cell Leukemia/lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Adult T-Cell Leukemia/lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Adult T-Cell Leukemia/lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Adult T-Cell Leukemia/lymphoma:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: leukemia-lymphoma, adult t-cell

Genetic Tests for Adult T-Cell Leukemia/lymphoma

Anatomical Context for Adult T-Cell Leukemia/lymphoma

Organs/tissues related to Adult T-Cell Leukemia/lymphoma:

MalaCards : T Cells, Skin, Bone, Liver, Breast, Spleen, Bone Marrow

Publications for Adult T-Cell Leukemia/lymphoma

Articles related to Adult T-Cell Leukemia/lymphoma:

(show top 50) (show all 5847)
# Title Authors PMID Year
1
Production and characterization of an active single-chain variable fragment antibody recognizing CD25. 53 62
15978327 2005
2
GPI-microdomains (membrane rafts) and signaling of the multi-chain interleukin-2 receptor in human lymphoma/leukemia T cell lines. 53 62
11856346 2002
3
Activation of interleukin-2 receptor alpha expression by extracellular HTLV-I Tax1 protein: a potential role in HTLV-I pathogenesis. 53 62
1501887 1992
4
Hypercalcemia and production of parathyroid hormone-like protein in adult T-cell leukemia-lymphoma. 53 62
1644163 1992
5
HTLV-1 p27rex stabilizes human interleukin-2 receptor alpha chain mRNA. 53 62
2249670 1990
6
Rearrangement of human T cell receptor beta and gamma chain genes in adult T cell leukemia/lymphoma. 53 62
2160910 1990
7
ANK Therapeutic Prospects and Usefulness of PD-L1 and NK Activity as Biomarkers for Predicting Treatment Efficacy Revealed from the Treatment Course of Patients with HTLV-1-Associated Bronchioloalveolar Disease. 62
36282976 2023
8
Increasing horizontal transmission of human T-cell leukemia virus type 1 in adolescents and young adults in Japan. 62
36370501 2022
9
Regulation of human T-cell leukemia virus type 1 antisense promoter by myocyte enhancer factor-2C in the context of adult T-cell leukemia and lymphoma. 62
35615924 2022
10
Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma. 62
35815408 2022
11
Prognostic role of controlling nutritional status score in hematological malignancies. 62
35622088 2022
12
Molecular insight into the study of adult T-cell leukemia/lymphoma (ATLL): Ten-year studies on HTLV-1 associated diseases in an endemic region. 62
36108787 2022
13
A frequent PLCγ1 mutation in adult T-cell leukemia/lymphoma determines functional properties of the malignant cells. 62
36442790 2022
14
Landscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia-lymphoma. 62
36420800 2022
15
Circulating clover-leaf cells presenting in acute-type adult T-cell leukemia-lymphoma. 62
36467847 2022
16
Radiation Recall Dermatitis after Donor Lymphocyte Infusion for Adult T cell Leukemia Lymphoma post Allogeneic Stem Cell Transplant. 62
36347452 2022
17
Pseudo-progression of adult T-cell leukemia-lymphoma after cord blood transplantation. 62
35734929 2022
18
HTLV-I associated bronchioloalveolar disorder (HABA): disease concept and differential diagnosis of an unsolved disease entity. 62
36437745 2022
19
Endothelial function testing before conditioning therapy is useful for predicting transplant-related complications after allogeneic hematopoietic cell transplantation. 62
36436130 2022
20
CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma. 62
36446869 2022
21
Cholesterol metabolism and lipid droplet vacuoles; a potential target for the therapy of aggressive lymphoma. 62
36436934 2022
22
Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. 62
35921533 2022
23
Development of a Novel HTLV-1 Protease: Human Fcγ1 Recombinant Fusion Molecule in the CHO Eukaryotic Expression System. 62
36399306 2022
24
Establishment of a Cynomolgus Macaque Model of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Direct Inoculation of Adult T-Cell Leukemia Patient-Derived Cell Lines for HTLV-1 Infection. 62
36314828 2022
25
Majocchi Granuloma in a Patient with Adult T-cell Leukemia. 62
36409384 2022
26
Acute type adult T-cell leukemia cells proliferate in the lymph nodes rather than in peripheral blood. 62
35459881 2022
27
Frequency and characteristics of HTLV in migrants: results from the +Redivi collaborative network in Spain. 62
35166822 2022
28
Selective APC-targeting of a novel Fc-fusion multi-immunodominant recombinant protein (tTax-tEnv:mFcγ2a) for HTLV-1 vaccine development. 62
36044973 2022
29
Valemetostat Tosilate: First Approval. 62
36380144 2022
30
Diagnostic utility of the aberrant immunohistochemical expression of CD3 molecules for peripheral T-cell lymphomas. 62
35905535 2022
31
Breast T-Lymphoblastic Lymphoma Presenting as a Single Mass in a Young Female with Family History of Breast Cancer. 62
35188824 2022
32
Live attenuated VZV vaccination induces antitumor immunity in ATLL patients. 62
36181532 2022
33
Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study. 62
36308678 2022
34
Primary Effusion Lymphoma-like ATL Developing During Hemodialysis. 62
36261387 2022
35
HTLV infection in Brazil's second-largest indigenous reserve. 62
36202887 2022
36
Diagnosis and Early Prediction of Lymphoma Using High-Throughput Clonality Analysis of Bovine Leukemia Virus-Infected Cells. 62
36227090 2022
37
Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma. 62
35122292 2022
38
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. 62
35417939 2022
39
[Clinical Study of Chemotherapy Combined with Antivirals for Adult T-cell Leukemia/Lymphoma]. 62
36208242 2022
40
The importance of the clinical classification of adult T-cell leukemia/lymphoma (ATLL) in the prognosis. 62
36260617 2022
41
ETS1 is a novel transcriptional regulator of adult T-cell leukemia/lymphoma of North American descent. 62
35675522 2022
42
Signaling factors potentially associated to the pathogenesis of Adult T-cell leukemia /lymphoma: A network-analysis and novel findings assessment. 62
35868352 2022
43
Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma. 62
36310058 2022
44
Gamma-secretase inhibitor does not induce cytotoxicity in adult T-cell leukemia cell lines despite NOTCH1 expression. 62
36243685 2022
45
Particularities of Neurological Manifestations in Adult T-Cell Leukemia/Lymphoma: Need for a Multidisciplinary Approach-A Narrative Review. 62
36363509 2022
46
TCL-150 Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma. 62
36164124 2022
47
Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study. 62
36083572 2022
48
Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract. 62
36039651 2022
49
Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth. 62
36047964 2022
50
HTLV-1-related adult T-cell leukemia/lymphoma: insights in early detection and management. 62
35880453 2022

Variations for Adult T-Cell Leukemia/lymphoma

Expression for Adult T-Cell Leukemia/lymphoma

Search GEO for disease gene expression data for Adult T-Cell Leukemia/lymphoma.

Pathways for Adult T-Cell Leukemia/lymphoma

GO Terms for Adult T-Cell Leukemia/lymphoma

Cellular components related to Adult T-Cell Leukemia/lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.4 IL2RA ICOSLG CD8A CD4 CD2 CCR6

Biological processes related to Adult T-Cell Leukemia/lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.15 IL2RA IL2 CD8A CD7 CD4 CCR6
2 immune system process GO:0002376 9.8 IL2RA IL2 ICOSLG CD8A CD7 CD4
3 positive regulation of activated T cell proliferation GO:0042104 9.63 IL2RA IL2 ICOSLG
4 negative regulation of lymphocyte proliferation GO:0050672 9.58 IL2RA IL2
5 regulation of T cell homeostatic proliferation GO:0046013 9.56 IL2 IL2RA
6 T cell activation GO:0042110 9.32 ICOSLG CD8A CD7 CD4 CD2
7 regulation of CD4-positive, alpha-beta T cell proliferation GO:2000561 9.26 IL2RA IL2

Sources for Adult T-Cell Leukemia/lymphoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....